Targeted-Chemotherapy of Cancer with Monoclonal Antibodies
The concept of targeted-chemotherapy harks back to the "magic bullet" of Paul Ehrlich. It has not yet been possible to achieve a "magic bullet" for cancer through the techniques of ordinary chemotherapy because of a lack of clear-cut biochemical differences between neo-plastic and normal cells. Targeted-chemotherapy with monoclonal antibodies is a new approach, combining the specificity of immunochemistry with the pharmacology of classical chemotherapeutics, promising to realize a "magic bullet" for cancer in the forseeable future.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Publication date: 1982-03-01
More about this publication?
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
- Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- Ingenta Connect is not responsible for the content or availability of external websites